Literature DB >> 3361581

Nonsteroidal antiandrogens. Synthesis and structure-activity relationships of 3-substituted derivatives of 2-hydroxypropionanilides.

H Tucker1, J W Crook, G J Chesterson.   

Abstract

A series of 3-(substituted thio)-2-hydroxypropionanilides and some corresponding sulfones and sulfoxides of general structure 7, in which R' is methyl or trifluoromethyl, were prepared and tested for antiandrogen activity. Members of the trifluoromethyl series (7, R' = CF3) generally exhibited partial androgen agonist activity whereas the members of the methyl series (7, R' = CH3) were pure antagonists. Lead optimization in the methyl series has led to the discovery of novel, potent antiandrogens, which are peripherally selective. One of these, (RS)-4'-cyano-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methyl-3'- (trifluoromethyl)propionanilide, 40 (ICI 176334), is being developed currently for the treatment of androgen-responsive benign and malignant disease.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3361581     DOI: 10.1021/jm00400a011

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  15 in total

Review 1.  Discovery and therapeutic promise of selective androgen receptor modulators.

Authors:  Jiyun Chen; Juhyun Kim; James T Dalton
Journal:  Mol Interv       Date:  2005-06

2.  Arylisothiocyanato selective androgen receptor modulators (SARMs) for prostate cancer.

Authors:  Dong Jin Hwang; Jun Yang; Huiping Xu; Igor M Rakov; Michael L Mohler; James T Dalton; Duane D Miller
Journal:  Bioorg Med Chem       Date:  2006-07-07       Impact factor: 3.641

3.  Structural basis for antagonism and resistance of bicalutamide in prostate cancer.

Authors:  Casey E Bohl; Wenqing Gao; Duane D Miller; Charles E Bell; James T Dalton
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-15       Impact factor: 11.205

4.  In vitro and in vivo structure-activity relationships of novel androgen receptor ligands with multiple substituents in the B-ring.

Authors:  Jiyun Chen; Dong Jin Hwang; Kiwon Chung; Casey E Bohl; Scott J Fisher; Duane D Miller; James T Dalton
Journal:  Endocrinology       Date:  2005-09-15       Impact factor: 4.736

Review 5.  Androgen receptors, sex behavior, and aggression.

Authors:  Rebecca L Cunningham; Augustus R Lumia; Marilyn Y McGinnis
Journal:  Neuroendocrinology       Date:  2012-09-14       Impact factor: 4.914

Review 6.  Recent Progress and Emerging Technologies towards a Sustainable Synthesis of Sulfones.

Authors:  Shuai Liang; Kamil Hofman; Marius Friedrich; Julian Keller; Georg Manolikakes
Journal:  ChemSusChem       Date:  2021-10-13       Impact factor: 9.140

7.  Growth inhibition of DMBA-induced rat mammary carcinomas by the antiandrogen flutamide.

Authors:  G Boccuzzi; E Tamagno; E Brignardello; M Di Monaco; M Aragno; O Danni
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

8.  Antiproliferative activity of casodex (ICI 176.334) in hormone-dependent tumours.

Authors:  A Maucher; E von Angerer
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

9.  Inhibition of Androgen Receptor Function and Level in Castration-Resistant Prostate Cancer Cells by 2-[(isoxazol-4-ylmethyl)thio]-1-(4-phenylpiperazin-1-yl)ethanone.

Authors:  Khalid Z Masoodi; Kurtis Eisermann; Zhenyu Yang; Javid A Dar; Laura E Pascal; Minh Nguyen; Katherine O'Malley; Erica Parrinello; Firuz G Feturi; Alex N Kenefake; Joel B Nelson; Paul A Johnston; Peter Wipf; Zhou Wang
Journal:  Endocrinology       Date:  2017-10-01       Impact factor: 4.736

10.  Metallocenes as Target Specific Drugs for Cancer Treatment.

Authors:  Enrique Meléndez
Journal:  Inorganica Chim Acta       Date:  2012-06-21       Impact factor: 2.545

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.